CJC-1295 dosing varies based on formulation
BPC-157 Supports Vascular and Neurological Repair One underappreciated hallmark of long COVID is endothelial dysfunction damage to the lining of blood vessels that impairs circulation, oxygenation, and tissue delivery.7 BPC-157 has demonstrated angiogenic (new blood vessel formation) effects in research models, upregulating VEGFR2 and promoting collateral circulation in ischemic tissue.8 This matters for two reasons: Cardiovascular symptoms (breathlessness, reduced exercise tolerance, tachycardia) may partly reflect impaired tissue oxygenation from vascular damage Neurological symptoms (brain fog, cognitive impairment) may similarly reflect reduced cerebral blood flow BPC-157's neuroprotective effects shown across models of traumatic brain injury, dopamine dysregulation, and serotonin syndrome also suggest value in supporting the neurotransmitter disruption many long COVID patients experience.9 BPC-157 Modulates Inflammation Without Immune Suppression This is critical
Third, individual variation is substantial: patients with severe insulin resistance or significant mitochondrial dysfunction may respond at lower doses than metabolically healthy athletes
Animal Data Is Substantial Multiple peer-reviewed rodent studies show accelerated tendon healing, gastroprotection, and bone repair
Abnormalities in MUC5AC and MUC5B protein in airway mucus in asthma
